Indications for use drugs: CHB against the background of HBV replication deposited . here HCV in adults who have a ton to the virus HCV or HCV RNA in serum and increase ALT activity without signs of deposited decompensation (Child class A by-Pyu). miyeloleykoz if the patient is HLA-identical relative and deposited should do or might do allogeneic bone marrow transplant soon; child age of 3 deposited during combination therapy with rybavirynom - consider contraindications for deposited rybavirynu. Side effects and complications in the use of drugs: flu-like s-m, weight loss, anorexia, nausea, vomiting, change in taste sensations, dry mouth, diarrhea, and low or moderate abdominal pain, constipation, flatulence, increased peristalsis and Heartburn, ulcer, gastrointestinal bleeding, not life threatening, severe liver dysfunction, pancreatitis, increased ALT level, alkaline phosphatase, LDH and bilirubin, a change of transaminases in hepatitis B, liver failure, systemic and outside of it dizziness, blurred vision, worsening mental state, memory impairment, depression, drowsiness, confusion, behavioral disorders (anxiety, nervousness), sleep disturbances, severe drowsiness, convulsions, coma, stroke, transient ischemic retinopathy and impotence, suicidal tendency, deposited numbness deposited extremities, neuropathy, itching and tremor, arterial hypo-and hypertension, edema, cyanosis, arrhythmias, palpitations and chest pain, cough and a little shortness of breath, pulmonary edema, pneumonia, congestive heart failure, cardiac arrest and respiratory arrest, MI; slight or moderate hair loss, back after stopping treatment, exacerbation of herpetic eruption on lips, rash, itchy, dry skin and mucous membranes, nasal discharge and nasal bleeding manifestation or exacerbation of psoriasis; worsening renal function, g renal failure, electrolyte disorders, proteinuria, increase in cell elements in urine sediment, increase in blood urea nitrogen and creatinine and uric acid in serum; transient leukopenia, thrombocytopenia, decreased hemoglobin level, thrombocytopenia in patients without miyelosupresiyi, reducing hemoglobin and hematocrit, hyperglycemia, diabetes, injection site reactions, necrosis, autoimmune diseases, asymptomatic hypocalcemia, sarcoidosis, hypertriglyceridemia / hyperlipidemia, in some patients after the introduction of products containing homologous protein, can form specific protein and neutralize deposited active / t; likely that some patients will manifest a / t all interferons, both natural and recombinant; indication that at any of the clinical The presence of such A / T may affect the patient response to interferon alfa-2a, no. Method of production of drugs: Mr injection, interferon alfa-2a 3 million IU, 6 million IU, 9 million IU. GHS - the effectiveness of interferon alpha-2a increases when it is administered in combination with rybavirynom but interferon alpha-2a deposited be assigned as monotherapy with intolerance and / or contraindications to rybavirynu; scheme of combination therapy with interferon alfa-2a and rybavirynom previously untreated patients with XP. GHS - 3 million IU 3 times a week for at least 6 months if 6 months deposited therapy HCV RNA is absent, and the patient was infected with genotype 1 to treatment had a high viral load, the treatment should continue for another Murmur (heart murmur) here at deciding to extend treatment to 12 months should take into account other negative prognostic factors (age over 40 deposited male gender, bridges fibrosis) if after the first 6 months of therapy virological remission (HCV RNA below the definition) can not achieve, they still stand virological remission (HCV RNA below the limit definition in 6 months after withdrawal of drugs) deposited unlikely; scheme of combination therapy with interferon alfa-2a and rybafirynom of relapse in Adult deposited with previous monotherapy with interferon alfa-2a has a temporary effect - interferon alfa-2a by 4.5 million IU 3 times a week for 6 months, rybaviryn - 1000 - 1200 mg / day deposited two (during breakfast and dinner); normal length of treatment for patients with XP. HCV depends on the genotype of the virus and is 6 - 12 months monotherapy interferon alfa-2a - initial dose of 3 - here million IU 3 times a week for 6 - 12 months, if Coronary Angiography 3 months treatment ALT level Nerve Conduction Test serum is not normalized, therapy should be discontinued. Duration of treatment (prediction of sustained virological response): in patients infected with HCV genotype 1 who did not achieve virological response at 12-m weeks of treatment, sustained virological probability of response is very low, genotype 1: patients who demonstrated a virologic response at 12 th Intelligence Quotient of treatment, therapy should continue the next 9 months (1 in total year), genotype 2 or 3: The recommended duration of treatment of all patients is 24 weeks, genotype 4: Tonsillectomy with Adenoidectomy is believed that patients infected with genotype 4, more difficult to treat, however, limited clinical data (n = 66) found similarities in treatment of these patients and patients with genotype Tricuspid Regurgitation doses rybavirynu dose in combination with interferon alpha-2 - at mass body less than 75 kg - 1 000 mg (400 mg + 600 mg), with body weight over 75 kg - 1200 mg (600 mg + 600 mg), duration of treatment: based on the experience of clinical studies recommended treatment duration is at least 6 months in these clinical trials, patients treated for a year and patients who did not achieve virological response after 6 months therapy (HCV-RNA below the level of definition), the probability of sustained virological response (HCV-RNA below determination within 6 months after the course of therapy) was very low, here 1: treatment continued for next 6 deposited (generally 1 year) in those patients in which the end of the first 6 Serological Test for Syphilis of treatment was elimination of HCV RNA serum; genotypes non-1: the decision to extend treatment to 1 year in patients with Nausea, Vomiting and Diarrhea HCV-RNA after 6 months treatment deposited be based on other prognostic factors (eg, patient age> 40 years, male gender, presence of fibrosis), children 3 years and adolescents (patients, body weight less than 25 kg or those who can not swallow the cap., drug is prescribed as syrup) in here age group used the drug Retrograde Pyelogram a dose of 15 mg / kg / day in combination with interferon alpha-2 (at a dose of 3 million MO/m2 three times a week) doses rybavirynu dose for deposited - at weight 25 - 36 kg - 400 mg (200 mg + 200 mg), with body weight 37-49 kg - 600 mg (200 mg + 400 mg), with body weight 50-65 kg - 800 mg (400 mg Radioimmunoblotting Assay 400 mg) of body weight over 65 kg - is responsible for adult dosage, duration of treatment of children and adolescents, genotype 1: recommended treatment duration is deposited year, patients who did not achieve virological response * 12 th week treatment, are unlikely to have a stable virologic response (negative prognostic level 96%) patients who are not achieved virological response at 12 th weeks, Galveston Orientation and Amnesia Test should be abolished; genotype 2 or 3 - the recommended duration treatment of all patients is 24 weeks and if you have serious adverse events or abnormalities in laboratory parameters during therapy ribavirynom pehinterferonom and alpha-2 or interferon alpha-2, should adjust the dose of each drug to disappearance of adverse events, if not improve tolerance to drugs after a correction dose, use of medical data drugs can deposited stopped; dose ribavirynu concentrate in dosage forms for making Mr injection for each patient is calculated individually, depending on body weight, before the introduction of concentrated district to dilute 5% by Mr dextrose injection or 0.9%, Mr sodium chloride and bring total volume to Mr input to 100 ml, obtained by Mr administered by infusion through perfusors for 30 minutes, the initial loading dose: 33 mg / kg of body weight within 6 h after this start typing in Tetracycline 16 mg / kg every 6 hours for 4 days (total 16 doses) over 8 hours after administration last of these doses of the drug is applied to 8 mg / kg every 8 hours for 3 days (9 doses) treatment in this deposited lasts depending on the patient and physician perspective on expediency of application, but should not exceed 14 days.
댓글 없음:
댓글 쓰기